Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate

NCT02581839 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.

NCT NCT02581839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02581839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Lead sponsor
Case Comprehensive Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
November 17, 2015
Completion date
July 2, 2020
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, metastatic breast cancer